Immunic to Announce Q3 2024 Financial Results and Corporate Update

**Immunic, Inc. Announces Third Quarter Financial Results Release and Webcast**

New York, October 31, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focused on developing orally administered treatments for chronic inflammatory and autoimmune diseases, is set to release its financial results for the third quarter ending September 30, 2024. Along with these results, the company will provide a corporate update on Thursday, November 7, 2024, prior to the opening of U.S. financial markets. Following this release, a webcast will take place at 8:00 am ET.

Participants interested in joining the webcast are encouraged to pre-register through Immunic's website under the "Events and Presentations" section. Registration will provide a confirmation email with instructions for online participation or a telephone number for dial-in access. Additionally, an archived version of the webcast will be accessible on the company's website approximately one hour after the live event concludes.

**About Immunic, Inc.**

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company dedicated to developing a clinical pipeline of orally administered, small molecule therapies designed to treat chronic inflammatory and autoimmune diseases. The company’s flagship development program is vidofludimus calcium (IMU-838). This compound is in phase 3 and phase 2 clinical trials aimed at treating relapsing and progressive multiple sclerosis, respectively. Vidofludimus calcium has demonstrated positive therapeutic effects in phase 2 trials involving patients with relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis.

Vidofludimus calcium works by activating the nuclear receptor related 1 (Nurr1), providing neuroprotective benefits. Additionally, it inhibits the enzyme dihydroorotate dehydrogenase (DHODH), leading to anti-inflammatory and antiviral properties. Another promising candidate from Immunic's pipeline is IMU-856, targeting the protein Sirtuin 6 (SIRT6). This potential treatment aims to restore intestinal barrier function and regenerate bowel epithelium, possibly benefitting a range of gastrointestinal conditions, including celiac disease. IMU-856 is currently being prepared for a phase 2 clinical trial.

An additional compound under development is IMU-381, which is in preclinical testing stages. This next-generation molecule is being tailored to address specific needs related to gastrointestinal diseases.

Immunic invites interested parties to remain updated on their progress and future plans by visiting their website for additional information.